MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-313

  1. 6,433 Posts.
    lightbulb Created with Sketch. 2621
    FDA had plenty of cover to approve because they had the 9-1 positive vote on the clinical data. They didn't need to worry about waiving any criteria.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.